Objectives
Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome measures in randomized controlled trials (RCTs) in CTD-ILD, but the lack of a systematically-developed, CTD-specific index that captures all measures, relevant and meaningful to CTD-ILD patients, has left a large and conspicuous gap in CTD-ILD research.
Methods
The CTD-ILD Working Group, under the aegis of OMERACT, has completed a consensus group exercise to reach harmony on core domains and items for inclusion in RCTs in CTD-ILD. During the OMERACT 12 meeting, consensus was sought after on the domains and core items for inclusion in RCTs. In addition, consensus was pursued on efinition of response in RCTs. Consensus was defined as ≥ 75% consensus.
Results
OMERACT 12 participants endorsed the domains with minimal modifications. Clinically meaningful progression for CTD-ILD was proposed as ≥10% relative decline in forced vital capacity (FVC)% or ≥5–<10% relative decline in FVC% and ≥15% relative decline in diffusion capacity in carbon monoxide (DLCO)%.
Conclusion
There is consensus on the domains for inclusion in RCTs in CTD-ILD and definition of clinically meaningful progression. Data-driven approaches will need to validate this in different cohorts and RCTs.